

Giulio Marchesini

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/8333779/publications.pdf](https://exaly.com/author-pdf/8333779/publications.pdf)

Version: 2025-02-01

339

PR articles

33,256

PR citations

5517

72

PR h-index

2403

177

g-index

388

documents

38335

doc citations

4835

81

h-index

34923

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Encased Heart â€“ A Very Rare Post Myocardial Infarction Complication Sequela. <i>Journal of Medical Science and Clinical Research</i> , 2024, 10, .	0.0	0
2	Long-term follow-up of web-based and group-based behavioural intervention in <scp>NAFLD</scp> in a real world clinical setting. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 59, 249-259.	3.9	10
3	Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2024, 25, 3168.	4.5	4
4	Metformin and the Liver: Unlocking the Full Therapeutic Potential. <i>Metabolites</i> , 2024, 14, 186.	3.5	28
5	Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?. <i>Digestive and Liver Disease</i> , 2024, 56, 1442-1451.	2.4	7
6	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	21.2	138
7	The treatment of diabetes in advanced liver disease: change of a paradigm. <i>Annals of Hepatology</i> , 2023, 28, 100772.	1.6	5
8	Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, 33, 640-648.	3.4	19
9	Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs. <i>Nutrients</i> , 2023, 15, 792.	4.7	11
10	Impact of migration on diabetes burden: audit in the metropolitan area of Bologna, Italy. <i>Journal of Endocrinological Investigation</i> , 2023, 47, 411-420.	3.0	3
11	Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM. <i>Diabetes Research and Clinical Practice</i> , 2023, 206, 111016.	6.2	24
12	Risk of binge eating disorder in patients with metabolic dysfunction-associated steatotic liver disease. <i>Eating and Weight Disorders</i> , 2023, 28, .	2.4	7
13	The Role of Psychological Well-Being in Weight Loss: New Insights from a Comprehensive Lifestyle Intervention. <i>International Journal of Clinical and Health Psychology</i> , 2022, 22, 100279.	4.3	14
14	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	52.8	547
15	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	3.4	24
16	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	2.4	28
17	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	3.6	219
18	A psycho-educational intervention for the prevention of foot lesions in people with diabetes: Report of a clinical audit. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	3.4	4

#	ARTICLE	IF	PR CITATIONS
19	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. Journal of Hepatology, 2021, 74, 972-974.	3.6	30
20	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. Liver International, 2021, 41, 731-742.	4.1	40
21	European "NAFLD Preparedness Index" Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	4.8	36
22	Incidence of diabetes mellitus in Italy in year 2018. A nationwide population-based study of the ARNO Diabetes Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2338-2344.	3.4	16
23	Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. Nutrients, 2021, 13, 2748.	4.7	82
24	Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2661-2668.	3.4	8
25	The Effect of Neuropathy and Diabetes Type on Multisegment Foot Kinematics: A Cohort Study on 70 Participants with Diabetes. Applied Sciences (Switzerland), 2021, 11, 8848.	2.2	2
26	Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports, 2021, 3, 100322.	4.8	189
27	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2021, 19, 60-78.	48.0	608
28	Analysis of Clinical Profiles, Deformities, and Plantar Pressure Patterns in Diabetic Foot Syndrome. Applied Sciences (Switzerland), 2021, 11, 11464.	2.2	2
29	Prognostic Value of Stress Hyperglycemia in Patients Admitted to Medical/Geriatric Departments for Acute Medical Illness. Diabetes Therapy, 2021, 13, 145-159.	2.1	5
30	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 935-944.e3.	6.2	144
31	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. Journal of Hepatology, 2020, 72, 14-24.	3.6	155
32	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. Hepatology, 2020, 71, 1213-1227.	10.6	273
33	A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1945-1953.	3.4	20
34	Stress Hyperglycemia and Mortality in Subjects With Diabetes and Sepsis. , 2020, 2, e0152.		45
35	Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory. BMJ Open Diabetes Research and Care, 2020, 8, e001191.	3.6	23
36	Correlations between weight-bearing 3D bone architecture and dynamic plantar pressure measurements in the diabetic foot. Journal of Foot and Ankle Research, 2020, 13, .	2.0	15

#	ARTICLE	IF	PR CITATIONS
37	Motivational Interviewing Adapted to Group Setting for the Treatment of Relapse in the Behavioral Therapy of Obesity. A Clinical Audit. <i>Nutrients</i> , 2020, 12, 3881.	4.7	9
38	Maternal PKU: Defining phenylalanine tolerance and its variation during pregnancy, according to genetic background. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 977-983.	3.4	9
39	Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders. <i>Acta Diabetologica</i> , 2020, 57, 1117-1119.	2.4	11
40	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1014-1022.	3.4	34
41	Nurse-managed basal-bolus versus sliding-scale insulin regimen in subjects with hyperglycemia at admission for orthopedic surgery: a propensity score approach. <i>Acta Diabetologica</i> , 2020, 57, 835-842.	2.4	14
42	Fatty liver in pregnancy: a narrative review of two distinct conditions. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 127-135.	2.5	29
43	<p>Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 9-17.	2.7	40
44	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. <i>Current Pharmaceutical Design</i> , 2020, 26, 1110-1118.	2.4	11
45	Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 983-990.	3.4	26
46	Combination of GLPǑ1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, .	2.6	13
47	Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2019, 8, 851.	2.6	23
48	Prevention and Treatment of Sarcopenic Obesity in Women. <i>Nutrients</i> , 2019, 11, 1302.	4.7	74
49	Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution. <i>BJR case Reports</i> , 2019, 5, 20170078.	0.2	10
50	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1087-1090.	2.2	4
51	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. <i>Nutrients</i> , 2019, 11, 3048.	4.7	37
52	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	52.8	1,092
53	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.	2.4	99
54	Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients. <i>Nutrition</i> , 2019, 61, 143-150.	2.9	20

#	ARTICLE	IF	PR CITATIONS
55	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. <i>Acta Diabetologica</i> , 2019, 57, 71-80.	2.4	25
56	Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution. <i>Acta Diabetologica</i> , 2019, 57, 115-116.	2.4	4
57	Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases. <i>Proceedings of the IEEE</i> , 2018, 106, 723-737.	9.6	43
58	Expected benefits and motivation to weight loss in relation to treatment outcomes in group-based cognitive-behavior therapy of obesity. <i>Eating and Weight Disorders</i> , 2018, 23, 205-214.	2.4	18
59	The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System. <i>Diabetes Therapy</i> , 2018, 9, 1037-1047.	2.1	11
60	DXA-assessed changes in body composition in obese women following two different weight loss programs. <i>Nutrition</i> , 2018, 46, 13-19.	2.9	10
61	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. <i>Hepatology</i> , 2018, 68, 349-360.	10.6	377
62	Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2018, 68, 361-371.	10.6	313
63	The Effect of Lutein on Eye and Extra-Eye Health. <i>Nutrients</i> , 2018, 10, 1321.	4.7	215
64	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. <i>Journal of Hepatology</i> , 2018, 69, 1155-1163.	3.6	110
65	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1903-1914.	2.2	24
66	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2711-2723.	4.7	20
67	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. <i>Cardiovascular Diabetology</i> , 2018, 17, .	9.9	66
68	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	3.6	1,708
69	Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice. <i>Journal of Endocrinological Investigation</i> , 2018, 42, 787-796.	3.0	3
70	Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. <i>Acta Diabetologica</i> , 2018, 56, 289-299.	2.4	19
71	The association between weight maintenance and session-by-session diet adherence, weight loss and weight-loss satisfaction. <i>Eating and Weight Disorders</i> , 2018, 25, 127-133.	2.4	20
72	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	2.4	277

#	ARTICLE	IF	PR CITATIONS
73	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , 2017, 389, 1399-1409.	52.8	709
74	Acute Heart Failure in the Emergency Department: the SAFE-SIMEU Epidemiological Study. <i>Journal of Emergency Medicine</i> , 2017, 53, 178-185.	0.8	2
75	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1594-1601.	4.7	20
76	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. <i>Digestive and Liver Disease</i> , 2017, 49, 235-240.	2.4	43
77	Long-term treatment of severe obesity: are lifestyle interventions still an option?. <i>Expert Review of Endocrinology and Metabolism</i> , 2017, 12, 391-400.	3.1	19
78	Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 1098-1107.	3.4	42
79	The Influence of Weight-Loss Expectations on Weight Loss and of Weight-Loss Satisfaction on Weight Maintenance in Severe Obesity. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2017, 117, 32-38.	1.6	33
80	Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 711-720.	2.1	3
81	Evidence-Based Medicine and the Problem of Healthy Volunteers. <i>Annals of Hepatology</i> , 2017, 16, 832-834.	1.6	11
82	Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control. <i>Journal of Endocrinological Investigation</i> , 2017, 41, 307-314.	3.0	17
83	Long-term weight loss maintenance for obesity: a multidisciplinary approach. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, , 37.	2.7	197
84	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2016, 95, e3446.	1.3	60
85	The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 944-950.	3.4	48
86	Response to letter to the editor: Gallo F et al., "The economic burden of severe hypoglycemia: Two sides of the same coin" <i>Nutr Metab Cardiovasc Dis.</i> 2016;26:850-851. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 851-852.	3.4	0
87	Costs associated with emergency care and hospitalization for severe hypoglycemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 345-351.	3.4	52
88	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 380-386.	3.4	31
89	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. <i>Diabetes and Metabolism</i> , 2016, 42, 142-156.	3.6	84
90	NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. <i>Current Hepatology Reports</i> , 2016, 15, 103-112.	0.7	3

#	ARTICLE	IF	PR CITATIONS
91	Incidence, prevalence, costs and quality of care of type 1 diabetes in Italy, age 0â€”29 years: The population-based CINECA-SID ARNO Observatory, 2002â€”2012. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 1104-1111.	3.4	14
92	Switching among Equivalents in Chronic Cardiovascular Therapies: â€”Real Worldâ€” Data from Italy. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 63-69.	2.9	1
93	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. Hepatology, 2016, 63, 2032-2043.	10.6	279
94	Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women. Journal of Sexual Medicine, 2016, 13, 46-54.	0.5	22
95	Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. Journal of Hepatology, 2016, 64, 262-264.	3.6	32
96	Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program. Internal and Emergency Medicine, 2016, 12, 45-52.	3.2	13
97	Evidence of a diurnal thermogenic handicap in obesity. Chronobiology International, 2015, 32, 299-302.	2.0	19
98	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 193-200.	4.2	28
99	Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease, 2015, 47, 181-190.	2.4	611
100	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. Journal of Hepatology, 2015, 62, 928-933.	3.6	183
101	Acute heart failure in the emergency department: a follow-up study. Internal and Emergency Medicine, 2015, 11, 115-122.	3.2	7
102	Aminotransferase and gamma-glutamyl transpeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. Journal of Endocrinological Investigation, 2014, 28, 333-339.	3.0	72
103	An empowerment-based educational program improves psychological well-being and health-related quality of life in Type 1 diabetes. Journal of Endocrinological Investigation, 2014, 29, 405-412.	3.0	17
104	Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica. L Endocrinologo, 2014, 8, 136-143.	0.0	0
105	Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. Journal of Endocrinological Investigation, 2014, 31, 146-152.	3.0	54
106	Impatto delle incretine sulla gestione del paziente diabetico: dati del monitoraggio antidiabetici AIFA. L Endocrinologo, 2014, 13, 210-215.	0.0	0
107	Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?. World Journal of Gastroenterology, 2014, 20, 10128.	4.8	30
108	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1346-1353.	3.4	42

#	ARTICLE	IF	PR CITATIONS
109	Sexuality and Psychopathological Aspects in Premenopausal Women with Metabolic Syndrome. <i>Journal of Sexual Medicine</i> , 2014, 11, 2020-2028.	0.5	26
110	A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry. <i>Nutrition</i> , 2014, 30, 696-701.	2.9	57
111	The Role of Medications for the Management of Patients with NAFLD. <i>Clinics in Liver Disease</i> , 2014, 18, 73-89.	3.7	28
112	Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes. <i>Acta Diabetologica</i> , 2014, 51, 559-566.	2.4	39
113	The influence of cognitive factors in the treatment of obesity: Lessons from the QUOVADIS study. <i>Behaviour Research and Therapy</i> , 2014, 63, 157-161.	3.8	43
114	A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, .	3.7	30
115	Liver in the analysis of body composition by dual-energy X-ray absorptiometry. <i>British Journal of Radiology</i> , 2014, 87, 20140232.	2.5	7
116	Risk of malnutrition (over and under-nutrition): Validation of the JaNuS screening tool. <i>Clinical Nutrition</i> , 2014, 33, 1087-1094.	5.6	13
117	Under-treatment of migrants with diabetes in a universalistic health care system: The ARNO Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 393-399.	3.4	30
118	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , 2014, 232, 99-109.	1.6	125
119	Visceral Fat and Body Composition Changes in a Female Population After RYGBP: a Two-Year Follow-Up by DXA. <i>Obesity Surgery</i> , 2014, 25, 443-451.	2.4	53
120	Obesity in the Context of Aging: Quality of Life Considerations. <i>Pharmacoeconomics</i> , 2014, 33, 655-672.	3.7	38
121	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523.	2.4	129
122	Eating behavior affects quality of life in type 2 diabetes mellitus. <i>Eating and Weight Disorders</i> , 2013, 10, 251-257.	2.4	21
123	Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones. <i>Drug Safety</i> , 2013, 35, 315-323.	2.9	36
124	Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH. <i>Hepatology International</i> , 2013, 7, 814-822.	4.5	9
125	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013, 59, 1169-1176.	3.6	35
126	Personality features of obese women in relation to binge eating and night eating. <i>Psychiatry Research</i> , 2013, 207, 86-91.	3.3	34

#	ARTICLE	IF	PR CITATIONS
127	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2013, 58, 771-777.	3.6	82
128	Emotionally focused group therapy and dietary counseling in binge eating disorder. Effect on eating disorder psychopathology and quality of life. <i>Appetite</i> , 2013, 71, 361-368.	2.9	26
129	Oral Branched-Chain Amino Acids Have a Beneficial Effect on Manifestations of Hepatic Encephalopathy in a Systematic Review with Meta-Analyses of Randomized Controlled Trials. <i>Journal of Nutrition</i> , 2013, 143, 1263-1268.	3.0	105
130	Health and ageing: A cross-sectional study of body composition. <i>Clinical Nutrition</i> , 2013, 32, 569-578.	5.6	76
131	Physical activity for the prevention and treatment of metabolic disorders. <i>Internal and Emergency Medicine</i> , 2013, 8, 655-666.	3.2	53
132	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β -Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2100-2105.	4.2	109
133	Longstanding underweight eating disorder: Associated features and treatment outcome. <i>Psychotherapy Research</i> , 2013, 23, 315-323.	3.0	16
134	Preliminary study about the possible glycemic clinical advantage in using a fixed combination of <i>Berberis aristata</i> and <i>Silybum marianum</i> standardized extracts versus only <i>Berberis aristata</i> in patients with type 2 diabetes. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, , 167.	1.1	48
135	Gender Difference in Hepatic Steatosis Index and Lipid Accumulation Product Ability to Predict Incident Metabolic Syndrome in the Historical Cohort of the Brisighella Heart Study. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 412-416.	2.1	26
136	A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. <i>Obesity</i> , 2013, 21, 1774-1781.	4.2	57
137	Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study. <i>Critical Care</i> , 2013, 17, .	7.8	66
138	Major factors for facilitating change in behavioral strategies to reduce obesity. <i>Psychology Research and Behavior Management</i> , 2013, , 101.	2.9	67
139	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2013, 8, e74089.	2.4	70
140	Personality Traits in Obesity Associated with Binge Eating and/or Night Eating. <i>Current Obesity Reports</i> , 2013, 3, 120-126.	9.7	10
141	Hepatic Encephalopathy and Health-Related Quality of Life. <i>Clinics in Liver Disease</i> , 2012, 16, 159-170.	3.7	30
142	Author's reply: Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 289-290.	2.2	0
143	Predicting unfavorable outcome in subjects with diagnosis of chest pain of undifferentiated origin. <i>American Journal of Emergency Medicine</i> , 2012, 30, 61-67.	1.7	4
144	Pathogenetic Mechanisms and Cardiovascular Risk. <i>Diabetes Care</i> , 2012, 35, 2607-2612.	6.5	38

#	ARTICLE	IF	PR CITATIONS
145	Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. <i>Hepatology</i> , 2012, 55, 1317-1323.	10.6	117
146	Diabetes and hepatocellular cancer risk: Not only a matter of hyperglycemia. <i>Hepatology</i> , 2012, 55, 1298-1300.	10.6	19
147	Prevalence of Sexual Dysfunction Among Postmenopausal Women with and Without Metabolic Syndrome. <i>Journal of Sexual Medicine</i> , 2012, 9, 434-441.	0.5	66
148	Objective and subjective binge eating in underweight eating disorders: Associated features and treatment outcome. <i>International Journal of Eating Disorders</i> , 2012, 45, 370-376.	4.1	21
149	Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?. <i>Metabolic Brain Disease</i> , 2012, 28, 221-225.	3.0	90
150	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2012, 7, e41183.	2.4	64
151	Night eating syndrome and weight loss outcome in obese patients. <i>International Journal of Eating Disorders</i> , 2011, 44, 150-156.	4.1	28
152	Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2657-2672.	2.2	20
153	Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2011, 43, 73-77.	2.4	15
154	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011, 43, 404-410.	2.4	29
155	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. <i>Journal of Hepatology</i> , 2011, 54, 1244-1249.	3.6	112
156	The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. <i>The ARNO Observatory. Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 339-346.	3.4	36
157	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 699-705.	3.4	18
158	Cognitive-Behavioral Strategies to Increase the Adherence to Exercise in the Management of Obesity. <i>Journal of Obesity</i> , 2011, 2011, 1-11.	3.8	169
159	Cognitive-Behavioral Treatment of Nonalcoholic Fatty Liver Disease: A Propensity Score-Adjusted Observational Study. <i>Obesity</i> , 2011, 19, 763-770.	4.2	48
160	Effects of Cognitive-Behavioral Treatment for Weight Loss in Family Members. <i>Journal of the American Dietetic Association</i> , 2011, 111, 1712-1719.	1.5	27
161	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , 2011, 48, 337-343.	2.4	24
162	Therapeutic hypothermia after cardiac arrest: The Mediterranean-diet Italian style. <i>Resuscitation</i> , 2011, 82, 637-638.	2.8	1

#	ARTICLE	IF	PR CITATIONS
163	Analysis of Different Decision Aids for Clinical Use in Pediatric Head Injury in an Emergency Department of a General Hospital. <i>Journal of Trauma</i> , 2011, 70, E79-E83.	2.2	6
164	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling—a propensity score-adjusted observational study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 141-149.	0.5	71
165	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. <i>Gut</i> , 2011, 60, 108-115.	21.2	33
166	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. <i>Acta Diabetologica</i> , 2011, 50, 569-577.	2.4	107
167	A psychological support program for individuals with Type 1 diabetes. <i>Acta Diabetologica</i> , 2011, 50, 209-216.	2.4	21
168	Effects of cognitive-behavioral therapy on Eating Disorders: Neurotransmitter secretory response to treatment. <i>Psychoneuroendocrinology</i> , 2010, 35, 729-737.	2.8	11
169	The changing face of mild head injury: Temporal trends and patterns in adolescents and adults from 1997 to 2008. <i>Injury</i> , 2010, 41, 913-917.	1.8	17
170	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2010, 51, 1158-1167.	10.6	393
171	Clinical and psychological correlates of health-related quality of life in obese patients. <i>Health and Quality of Life Outcomes</i> , 2010, 8, .	3.0	75
172	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, Volume 3, 373-385.	2.7	69
173	Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1275-1279.	7.3	38
174	Double Heterozygous Mutations Involving Both <i>HNF1A</i> and <i>MODY3</i> and <i>HNF4A</i> and <i>MODY1</i> Genes. <i>Diabetes Care</i> , 2010, 33, 2336-2338.	6.5	22
175	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2010, 59, 267-273.	21.2	166
176	Insulin Resistance in Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2010, 16, 1941-1951.	2.4	367
177	Prevention and treatment of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2010, 42, 331-340.	2.4	18
178	HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2010, 138, 905-912.	1.0	262
179	A position statement on NAFLD/NASH based on the EASL 2009 special conference. <i>Journal of Hepatology</i> , 2010, 53, 372-384.	3.6	963
180	Weight management, psychological distress and binge eating in obesity. A reappraisal of the problem. <i>Appetite</i> , 2010, 54, 269-273.	2.9	36

#	ARTICLE	IF	PR CITATIONS
181	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, , 373.	2.7	73
182	Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. World Journal of Gastroenterology, 2010, 16, 348.	4.8	42
183	ESPEN Guidelines on Parenteral Nutrition: Hepatology. Clinical Nutrition, 2009, 28, 436-444.	5.6	231
184	Psychological Variables Associated with Weight Loss in Obese Patients Seeking Treatment at Medical Centers. Journal of the American Dietetic Association, 2009, 109, 2010-2016.	1.5	74
185	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology, 2009, 49, 195-203.	10.6	66
186	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology, 2009, 50, 697-706.	10.6	143
187	Night eating syndrome in class II-III obesity: metabolic and psychopathological features. International Journal of Obesity, 2009, 33, 899-904.	3.2	51
188	Self-induced vomiting in eating disorders: Associated features and treatment outcome. Behaviour Research and Therapy, 2009, 47, 680-684.	3.8	30
189	Are behavioural approaches feasible and effective in the treatment of type 2 diabetes? A propensity score analysis vs. prescriptive diet. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 313-320.	3.4	21
190	Metabolic Syndrome and Insulin Resistance in Subjects with Morbid Obesity. Obesity Surgery, 2009, 20, 295-301.	2.4	31
191	Massive Weight Loss Without Surgery in a Super Obese Patient. Obesity Surgery, 2009, 21, 540-545.	2.4	4
192	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antiviral Therapy, 2009, 14, 631-639.	2.1	22
193	Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia, 2008, 51, 1947-1953.	8.6	388
194	Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression. Liver Transplantation, 2008, 14, 1648-1654.	2.6	259
195	Underweight eating disorder without overevaluation of shape and weight: Atypical anorexia nervosa?. International Journal of Eating Disorders, 2008, 41, 705-712.	4.1	46
196	Retinol-binding protein 4: A new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology, 2008, 48, 28-37.	10.6	57
197	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 2008, 48, 792-798.	10.6	649
198	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 624-631.	3.4	67

#	ARTICLE	IF	PR CITATIONS
199	Personality dimensions and treatment drop-outs among eating disorder patients treated with cognitive behavior therapy. <i>Psychiatry Research</i> , 2008, 158, 381-388.	3.3	22
200	Is amenorrhea a clinically useful criterion for the diagnosis of anorexia nervosa?. <i>Behaviour Research and Therapy</i> , 2008, 46, 1290-1294.	3.8	39
201	Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study. <i>Clinical Therapeutics</i> , 2008, 30, 1168-1176.	2.9	124
202	Compulsive exercise to control shape or weight in eating disorders: prevalence, associated features, and treatment outcome. <i>Comprehensive Psychiatry</i> , 2008, 49, 346-352.	4.3	354
203	Nutritional treatment of chronic liver failure. <i>Hepatology Research</i> , 2008, 38, .	3.1	22
204	Vascular Risk in Young Women With Polycystic Ovary and Polycystic Ovary Syndrome. <i>Obstetrics and Gynecology</i> , 2008, 111, 385-395.	1.4	47
205	Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 1136-1144.	0.7	172
206	Hepatotoxicity of fast food?. <i>Gut</i> , 2008, 57, 568-570.	21.2	24
207	Which Treatment for Nonalcoholic Fatty Liver Disease?. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 767-775.	2.6	9
208	Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study. <i>American Journal of Gastroenterology</i> , 2007, 102, 1251-1258.	0.7	282
209	Correspondence Between the International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance in a Cohort of Italian Nondiabetic Caucasians: The GISIR database. <i>Diabetes Care</i> , 2007, 30, e33-e33.	6.5	4
210	Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 493-498.	3.4	16
211	Diabetes and liver disease: An ominous association. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 63-70.	3.4	114
212	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 684-698.	3.4	64
213	The effect of inpatient cognitive-behavioral therapy for eating disorders on temperament and character. <i>Behaviour Research and Therapy</i> , 2007, 45, 1335-1344.	3.8	39
214	Metabolic Syndrome and NASH. <i>Clinics in Liver Disease</i> , 2007, 11, 105-117.	3.7	123
215	Essential hypertension and chronic viral hepatitis. <i>Digestive and Liver Disease</i> , 2007, 39, 466-472.	2.4	7
216	The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. <i>Hepatology</i> , 2007, 45, 846-854.	10.6	2,866

#	ARTICLE	IF	PR CITATIONS
217	The Effect of Obesity Management on Body Image in Patients Seeking Treatment at Medical Centers. <i>Obesity</i> , 2007, 15, 2320-2327.	4.2	40
218	Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 346-355.	2.7	30
219	The treatment of hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2007, 22, 389-405.	3.0	66
220	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. <i>Current Diabetes Reports</i> , 2007, 7, 175-180.	5.4	57
221	Psychological Distress in Morbid Obesity in Relation to Weight History. <i>Obesity Surgery</i> , 2007, 17, 391-399.	2.4	58
222	Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study. <i>International Journal of Obesity</i> , 2007, 32, 185-191.	3.2	74
223	Construct Validity of the Short Form-36 Health Survey and Its Relationship with BMI in Obese Outpatients. <i>Obesity</i> , 2006, 14, 1429-1437.	4.2	47
224	Monitoring intervention programmes for out-of-hospital cardiac arrest in a mixed urban and rural setting. <i>Resuscitation</i> , 2006, 71, 180-187.	2.8	34
225	Complexity of attrition in the treatment of obesity: clues from a structured telephone interview. <i>International Journal of Obesity</i> , 2006, 30, 1132-1137.	3.2	100
226	Disease Management of the Metabolic Syndrome in a Community: Study Design and Process Analysis on Baseline Data. <i>Metabolic Syndrome and Related Disorders</i> , 2006, 4, 7-16.	2.1	10
227	Response to Letter. <i>American Journal of Gastroenterology</i> , 2006, 101, 1396-1397.	0.7	3
228	Nonalcoholic fatty liver disease and the metabolic syndrome. <i>Current Opinion in Lipidology</i> , 2005, 16, 421-427.	4.1	320
229	Branched-Chain Amino Acid Supplementation in Patients with Liver Diseases. <i>Journal of Nutrition</i> , 2005, 135, 1596S-1601S.	3.0	72
230	Update on branched-chain amino acid supplementation in liver diseases. <i>Current Opinion in Gastroenterology</i> , 2005, 21, 197-200.	2.3	34
231	Update on nutritional supplementation with branched-chain amino acids. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2005, 8, 83-87.	3.2	39
232	A Positive Blood Alcohol Concentration Is the Main Predictor of Recurrent Motor Vehicle Crash. <i>Annals of Emergency Medicine</i> , 2005, 46, 161-167.	1.1	27
233	Weight Loss Expectations in Obese Patients and Treatment Attrition: An Observational Multicenter Study. <i>Obesity</i> , 2005, 13, 1961-1969.	4.2	260
234	Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. <i>Hepatology</i> , 2005, 42, 44-52.	10.6	1,157

#	ARTICLE	IF	PR CITATIONS
235	Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005, 42, 473-480.	10.6	575
236	Insulin resistance: A metabolic pathway to chronic liver disease. <i>Hepatology</i> , 2005, 42, 987-1000.	10.6	793
237	Clinical Performance of NICE Recommendations versus NCWFNS Proposal in Patients with Mild Head Injury. <i>Journal of Neurotrauma</i> , 2005, 22, 1419-1427.	3.7	47
238	Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3498-3504.	4.2	374
239	Is liver disease a threat to patients with metabolic disorders?. <i>Annals of Medicine</i> , 2005, 37, 333-346.	4.1	28
240	Psychological status and depression in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2005, 37, 593-600.	2.4	167
241	A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 1082-1090.	0.7	649
242	A physical activity program to reinforce weight maintenance following a behavior program in overweight/obese subjects. <i>International Journal of Obesity</i> , 2005, 30, 697-703.	3.2	33
243	A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department. <i>Emergency Medicine Journal</i> , 2004, 21, 317-322.	2.1	10
244	Nutritional therapy in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S401-S405.	2.7	0
245	Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study. <i>International Journal of Obesity</i> , 2004, 28, 1456-1462.	3.2	59
246	Weight Loss Expectations in Obese Patients Seeking Treatment at Medical Centers. <i>Obesity</i> , 2004, 12, 2005-2012.	4.2	68
247	Health-related quality of life in patients with thyroid disorders. <i>Quality of Life Research</i> , 2004, 13, 45-54.	2.1	140
248	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. <i>Hepatology</i> , 2004, 39, 179-187.	10.6	403
249	Plasma Ghrelin Concentrations, Food Intake, and Anorexia in Liver Failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2136-2141.	4.2	71
250	Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?. <i>Digestive and Liver Disease</i> , 2004, 36, 165-173.	2.4	79
251	Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. <i>Digestive and Liver Disease</i> , 2004, 36, 406-411.	2.4	41
252	Non-alcoholic steatohepatitis in patients cared in metabolic units. <i>Diabetes Research and Clinical Practice</i> , 2004, 63, 143-151.	6.2	21

#	ARTICLE	IF	PR CITATIONS
253	The metabolic syndrome in treatment-seeking obese persons. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 435-440.	9.5	50
254	Which type of observation for patients with high-risk mild head injury and negative computed tomography?. <i>European Journal of Emergency Medicine</i> , 2004, 11, 65-69.	1.3	16
255	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 1105-1116.	3.0	36
256	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 1105-1116.	3.0	32
257	Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. <i>Hepatology</i> , 2003, 37, 917-923.	10.6	2,375
258	Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. <i>Gastroenterology</i> , 2003, 124, 1792-1801.	1.0	589
259	Impaired insulin-mediated amino acid plasma disappearance in non-alcoholic fatty liver disease: a feature of insulin resistance. <i>Digestive and Liver Disease</i> , 2003, 35, 722-727.	2.4	23
260	Reduced quality of life of patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2003, 35, 46-54.	2.4	51
261	Low Ghrelin Concentrations in Nonalcoholic Fatty Liver Disease Are Related to Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5674-5679.	4.2	58
262	Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. <i>Gastroenterology</i> , 2002, 123, 134-140.	1.0	1,354
263	Effects of long-term oral misoprostol administration on hepatic amino acid nitrogen metabolism in patients with cirrhosis. <i>Journal of Hepatology</i> , 2002, 37, 15-21.	3.6	1
264	Homocysteine and psychological traits: a study in obesity. <i>Nutrition</i> , 2002, 18, 403-407.	2.9	17
265	Effects of cognitive behavioural therapy on health-related quality of life in obese subjects with and without binge eating disorder. <i>International Journal of Obesity</i> , 2002, 26, 1261-1267.	3.2	47
266	Factors associated with poor health-related quality of life of patients with cirrhosis. <i>Gastroenterology</i> , 2001, 120, 170-178.	1.0	458
267	Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcohol steatohepatitis. <i>Digestive and Liver Disease</i> , 2001, 33, 768-777.	2.4	17
268	Metformin in non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2001, 358, 893-894.	52.8	663
269	Blood Alcohol Concentration and Management of Road Trauma Patients in the Emergency Department. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 50, 521-528.	6.3	53
270	Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes. <i>Seminars in Liver Disease</i> , 2001, 21, 017-026.	3.4	536

#	ARTICLE	IF	PR CITATIONS
271	Nutritional effects of oral zinc supplementation in cirrhosis. <i>Nutrition Research</i> , 2000, 20, 1079-1089.	2.8	35
272	Synthesis of glutathione in response to methionine load in control subjects and in patients with cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 1434-1439.	9.5	28
273	Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. <i>Digestive and Liver Disease</i> , 2000, 32, 398-405.	2.4	45
274	Total and functional hepatic blood flow decrease in parallel with ageing. <i>Age and Ageing</i> , 1999, 28, 29-33.	1.8	152
275	Title is missing!. <i>Digestive Diseases and Sciences</i> , 1999, 44, 377-384.	2.3	8
276	Cardiovascular disease in cirrhosis A point-prevalence study in relation to glucose tolerance. <i>American Journal of Gastroenterology</i> , 1999, 94, 655-662.	0.7	58
277	Association of nonalcoholic fatty liver disease with insulin resistance. <i>American Journal of Medicine</i> , 1999, 107, 450-455.	2.3	1,481
278	Effects of Systemic Prostaglandin E1 on Splanchnic and Peripheral Haemodynamics in Control Subjects and in Patients with Cirrhosis. <i>Prostaglandins and Other Lipid Mediators</i> , 1998, 55, 209-218.	2.3	5
279	Effects of systemic prostaglandin e on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. <i>Hepatology</i> , 1998, 27, 815-821.	10.6	11
280	Zinc supplementation improves glucose disposal in patients with cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 792-798.	9.5	65
281	Quantification of gluconeogenesis in cirrhosis: Response to glucagon. <i>Gastroenterology</i> , 1998, 115, 1530-1540.	1.0	59
282	Gender-dependent alterations in serum leptin in alcoholic cirrhosis. <i>Gastroenterology</i> , 1998, 115, 947-953.	1.0	146
283	LONG-TERM MANAGEMENT OF ALCOHOLIC LIVER DISEASE. <i>Clinics in Liver Disease</i> , 1998, 2, 821-838.	3.7	4
284	Glutathione kinetics in normal man and in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 1997, 26, 606-613.	3.6	50
285	Overview of Randomized Clinical Trials of Oral Branched-Chain Amino Acid Treatment in Chronic Hepatic Encephalopathy. <i>Journal of Parenteral and Enteral Nutrition</i> , 1996, 20, 159-164.	3.4	70
286	Transamination of methionine after loading in patients with cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 95-100.	3.6	9
287	Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. <i>Journal of Hepatology</i> , 1996, 25, 474-480.	3.6	49
288	Transdermal nitroglycerin in cirrhosis. A 24-hour echo-Doppler study of splanchnic hemodynamics. <i>Journal of Hepatology</i> , 1996, 25, 498-503.	3.6	10

#	ARTICLE	IF	PR CITATIONS
289	Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. <i>Hepatology</i> , 1996, 23, 1084-1092.	10.6	91
290	Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. <i>Hepatology</i> , 1996, 24, 1047-1052.	10.6	38
291	The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death. <i>Hepatology</i> , 1996, 24, 820-823.	10.6	21
292	Thyroid volume in type 1 diabetes patients without overt thyroid disease. <i>Acta Diabetologica</i> , 1995, 32, 49-52.	2.4	12
293	Effects of beta-blockade on hepatic conversion of amino acid nitrogen and on urea synthesis in cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 899-905.	9.5	3
294	Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. <i>Journal of Hepatology</i> , 1995, 23, 129-134.	3.6	61
295	Prognostic significance of diabetes in patients with cirrhosis. <i>Hepatology</i> , 1994, 20, 119-125.	10.6	165
296	Hepatic conversion of amino-nitrogen to urea in thyroid diseases. II. A study in hyperthyroid patients. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 1023-1029.	9.5	7
297	Kinetics of hepatic amino-nitrogen conversion in ageing man. <i>Liver</i> , 1994, 14, 288-294.	0.0	24
298	Prognostic significance of diabetes in patients with cirrhosis*1. <i>Hepatology</i> , 1994, 20, 119-125.	10.6	177
299	Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: Dependence on liver cell failure. <i>Hepatology</i> , 1993, 18, 28-35.	10.6	19
300	Lactitol in treatment of chronic hepatic encephalopathy. <i>Digestive Diseases and Sciences</i> , 1993, 38, 916-922.	2.3	73
301	Thyroid involvement in chronic inflammatory rheumatological disorders. <i>Clinical Rheumatology</i> , 1993, 12, 479-484.	2.4	41
302	Hepatic conversion of amino nitrogen to urea nitrogen in hypothyroid patients and upon l-thyroxine therapy. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1263-1269.	9.5	21
303	Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. <i>Journal of Hepatology</i> , 1993, 17, 56-61.	3.6	91
304	Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. <i>Clinical Nutrition</i> , 1992, 11, 303-308.	5.6	15
305	Polyamine plasma levels and liver regeneration following partial hepatic resection in man. <i>Journal of Hepatology</i> , 1992, 16, 159-164.	3.6	9
306	Defective methionine metabolism in cirrhosis: Relation to severity of liver disease. <i>Hepatology</i> , 1992, 16, 149-155.	10.6	59

#	ARTICLE	IF	PR CITATIONS
307	Oral BCAA in the treatment of chronic hepatic encephalopathy. <i>Journal of Hepatology</i> , 1991, 12, 267.	3.6	6
308	Elimination of infused branched-chain amino-acids from plasma of patients with non-obese type 2 diabetes mellitus. <i>Clinical Nutrition</i> , 1991, 10, 105-113.	5.6	11
309	Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1197-1203.	2.3	88
310	Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: A simplified method. <i>Hepatology</i> , 1991, 13, 460-466.	10.6	34
311	Intérêt de l'administration par voie orale d'acides aminés à chaîne ramifiée chez le cirrhotique encéphalopathe chronique. <i>Nutrition Clinique Et Metabolisme</i> , 1991, 5, 207-214.	0.2	5
312	Glucose disposal, β_2 -cell secretion, and hepatic insulin extraction in cirrhosis: A minimal model assessment. <i>Gastroenterology</i> , 1990, 99, 1715-1722.	1.0	71
313	Mathematical model to analyse urea synthesis following alanine infusion in control subjects and in patients with liver cirrhosis. <i>Medical and Biological Engineering and Computing</i> , 1990, 28, 325-328.	2.4	1
314	Ultrasonographic follow-up of liver cirrhosis. <i>Journal of Clinical Ultrasound</i> , 1990, 18, 91-96.	1.1	25
315	Synthesis of Urea after a Protein-rich Meal in Normal Man in Relation to Ageing. <i>Age and Ageing</i> , 1990, 19, 4-10.	1.8	20
316	Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. <i>Journal of Hepatology</i> , 1990, 11, 92-101.	3.6	211
317	Carbohydrate metabolism in hepatocellular carcinoma: Where does the glucose go?. <i>Hepatology</i> , 1989, 10, 253-255.	10.6	8
318	Galactose elimination capacity and liver volume in aging man. <i>Hepatology</i> , 1988, 8, 1079-1083.	10.6	141
319	Insulin resistance in aged man: Relationship between impaired glucose tolerance and decreased insulin activity on branched-chain amino acids. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 1096-1100.	9.5	17
320	Plasma clearances of branched-chain amino acids in control subjects and in patients with cirrhosis. <i>Journal of Hepatology</i> , 1987, 4, 108-117.	3.6	55
321	Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1987, 32, 1118-1124.	2.3	19
322	Portal venous flow in response to acute β_2 -blocker and vasodilatory treatment in patients with liver cirrhosis. <i>Hepatology</i> , 1986, 6, 1248-1251.	10.6	77
323	Echo-doppler measurement of splanchnic blood flow in control and cirrhotic subjects. <i>Journal of Clinical Ultrasound</i> , 1986, 14, 429-435.	1.1	116
324	Degeneration of the corticospinal tract following portosystemic shunt associated with spinal cord infarction. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1985, 406, 475-481.	1.4	19

#	ARTICLE	IF	PR CITATIONS
325	Pancreatic β -cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal. <i>Metabolism: Clinical and Experimental</i> , 1985, 34, 695-701.	9.5	24
326	The Euglycemic Clamp Technique in Patients with Liver Cirrhosis. <i>Hormone and Metabolic Research</i> , 1984, 16, 341-343.	1.9	22
327	Insulin-dependent metabolism of branched-chain amino acids in obesity. <i>Metabolism: Clinical and Experimental</i> , 1984, 33, 147-150.	9.5	50
328	Plasma amino acid response to protein ingestion in patients with liver cirrhosis. <i>Gastroenterology</i> , 1983, 85, 283-290.	1.0	39
329	Effect of Euglycemic Insulin Infusion on Plasma Levels of Branched-Chain Amino Acids in Cirrhosis. <i>Hepatology</i> , 1983, 3, 184-187.	10.6	33
330	Ammonia-induced changes in pancreatic hormones and plasma amino acids in patients with liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1982, 27, 406-412.	2.3	17
331	Muscle protein breakdown in uncontrolled diabetes as assessed by urinary 3-methylhistidine excretion. <i>Diabetologia</i> , 1982, 23, .	8.6	28
332	Branched-chain amino acids and alanine as indices of the metabolic control in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1982, 22, .	8.6	41
333	Anticatabolic Effect of Branched-Chain Amino Acid-Enriched Solutions in Patients With Liver Cirrhosis. <i>Hepatology</i> , 1982, 2, 420S-425S.	10.6	89
334	Plasma Amino Acids as Markers of Liver Dysfunction in Cirrhotics. <i>Scandinavian Journal of Gastroenterology</i> , 1981, 16, 689-692.	1.8	11
335	Muscle protein breakdown in liver cirrhosis and the role of altered carbohydrate metabolism. <i>Hepatology</i> , 1981, 1, 294-299.	10.6	89
336	Prevalence of subclinical hepatic encephalopathy in cirrhotics and relationship to plasma amino acid imbalance. <i>Digestive Diseases and Sciences</i> , 1980, 25, 763-768.	2.3	62
337	Insulin and glucagon levels in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1979, 24, 594-601.	2.3	81
338	Branched-chain amino acids for people with hepatic encephalopathy. <i>The Cochrane Library</i> , 0, , .	2.4	162
339	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 0, , m4747.	0.2	137